47 results on '"Bergenheim K"'
Search Results
2. HSD27 Constrained Optimization Model to Estimate Best Booster Allocation Strategy to Minimize Hospital Bed-Days Under a Fixed Healthcare Budget
3. POSC306 Data Sources for Chronic Kidney Disease Models in Type 2 Diabetes: Classic Studies, Country-Specific Data, and Recent Outcomes Trials
4. POSB313 Predicting Chronic Kidney Disease in Type 2 Diabetes Using Patient-level Simulation: Outcomes, Markers, Risk Factors, and Sequelae Identified in a Systematic Review
5. POSC353 Quality of Life in Chronic Kidney Disease (CKD): Results from a Systematic Review of CKD Models for Type 2 Diabetes
6. POSB312 Markov Models for Chronic Kidney Disease in Type 2 Diabetes: Differences and Commonalities in Model Structures and Modeled Health States
7. POS-335 COST-EFFECTIVENESS OF DAPAGLIFLOZIN AS A TREATMENT FOR CHRONIC KIDNEY DISEASE: A HEALTH-ECONOMIC ANALYSIS OF DAPA-CKD
8. PCV45 Cost-Effectiveness of Dapagliflozin Versus Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction
9. PMU10 - USE OF A LIFETIME SIMULATION MODEL TO QUANTIFY THE IMPACT OF HYPERKALAEMIA ON PREDICTED AND QUALITY-ADJUSTED LIFE EXPECTANCY IN PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE
10. Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA1c , weight and hypoglycaemic event incidence
11. A Model To Predict Costs And Outcomes Associated With Hyperkalaemia In Patients With Chronic Kidney Disease Or Heart Failure
12. P4901Association between serum potassium and clinical outcomes in UK patients with heart failure
13. Payer Requirements in the Treatment of Chronic Heart Failure
14. Quantifying the Health Economic Value Associated with Unit Changes in HBA1C in Type 1 Diabetes Mellitus
15. Flexibly Modelling HBA1C Progression in Type 2 Diabetes to Estimate the Impact of Clinical Inertia on Costs and Quality Adjusted Life Years
16. The Role of Weight Loss or Gain In Payer Assessment of Diabetes Drugs
17. ALTERNATIVE APPROACHES TO MODELLING HBA1C PROGRESSION IN TYPE 2 DIABETES AND THEIR IMPACT ON HEALTH ECONOMIC OUTCOMES
18. Network meta-analysis of treatments for type 2 diabetes mellitus following failure with metformin plus sulfonylurea
19. A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus
20. Understanding The Inter-Relationship Between Improved Glycaemic Control, Hypoglycaemia and Weight Change Within A Type 1 Diabetic Population
21. Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
22. The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
23. Comparing the Event Prediction Capability of the Ukpds68 and Hong Kong Diabetes Risk Equations within A Type 2 Diabetes Simulation Model
24. Comparing the Use of Patient-Level Data to An Average Patient Profile Within a Type 2 Diabetes Simulation Model
25. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK
26. The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus a DPP-4 Inhibitor in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
27. The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Insulin in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
28. The Cost-Effectiveness of Dapagliflozin (Forxiga®) Versus Glipizide in the Treatment of Type 2 Diabetes Mellitus (T2DM) in England and Wales
29. Investigating the Validity of the UKPDS Outcomes Equations in Current Clinical Practice
30. Cost of Achieving Relevant Composite Endpoint of HbA1c<7%, No Hypoglycaemia and Weight Loss of ≥3% in a 52 Week Post-Hoc Analysis of Dapagliflozin Versus Glipizide
31. Cost-Effectiveness of Dapagliflozin as Add-On to Insulin for the Treatment of Type 2 Diabetes in the Netherlands
32. PDB66 Quantifying the Impact of Poor Glycaemic Control Compared With Guidelines in the Treatment of Type 2 Diabetes in UK Clinical Practice
33. PDB53 Cost-Effectiveness of Saxagliptin (Onglyza®) in Type 2 Diabetes in South Africa
34. PDB62 The Impact of Clinical Inertia in the Treatment of Type 2 Diabetes
35. PDB47 Understanding the Implications of Incorporating the UKPDS Glycaemic Legacy Effect Into Evaluating the Cost-Effectiveness of Type 2 Diabetes Therapies
36. PDB50 ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL
37. PDB44 THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS SULFONYLUREA (SU) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN GERMANY
38. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model
39. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
40. PMC21 ASSESSING THE RELATIONSHIP BETWEEN COMPUTATIONAL SPEED AND PRECISION: A CASE STUDY USING A DISCRETE EVENT SIMULATION MODEL IN DIABETES CARE
41. PDB14 MODELLING THE EFFECTIVENESS OF ORAL AGENTS IN ACHIEVING HBAICAND LIPID TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
42. PDB23 EXTERNAL VALIDATION OF THE UKPDS OUTCOMES MODEL EQUATIONS (UKPDS 68), AND THE UKPDS RISK ENGINE EQUATIONS (UKPDS 56 AND 60) IN FORECASTING CARDIOVASCULAR OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES
43. PGI23 ESOMEPRAZOLE TREATMENT IN PATIENTS WITH UNINVESTIGATED NON-GERD DYSPEPSIA LEADS TO SIGNIFICANT IMPROVEMENTS IN PRODUCTIVITYWHILE ATWORKAND IN DAILY ACTIVITIES—RESULTS FROMA RANDOMISED, PLACEBO-CONTROLLED CLINICAL STUDY
44. PDB26 THE IMPACT OF VASCULAR EVENTS ON HEALTH-RELATED UTILITY IN PATIENTS WITH AND WITHOUT TYPE-2 DIABETES
45. PDB15 TOTAL CHOLESTEROL, HDL CHOLESTEROL AND HBA1C AFFECT QUALITY-ADJUSTED LIFE YEARS AND HOSPITAL COSTS FOR PATIENTS WITH TYPE 2 DIABETES IN THE UNITED KINGDOM–THE CARDIFF DIABETES COST UTILITY MODEL
46. PGS12 IMPACT ON WORK PRODUCTIVITY OF UPPER GASTROINTESTINAL SYMPTOMS ASSOCIATED WITH CHRONIC NSAID THERAPY IN A SWEDISH STUDY POPULATION
47. Systematic review: patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.